AlloVir, Inc. (ALVR) Stock Analysis

AlloVir, Inc. (ALVR) Healthcare & Pipeline Overview

AlloVir, Inc. pioneers off-the-shelf multi-virus specific T cell therapies, targeting a range of viral-associated diseases. Their lead candidate, posoleucel, addresses critical unmet needs in treating BK virus, cytomegalovirus, and other viral infections, positioning them in the forefront of allogeneic cell therapy within the biotechnology sector.

What Is the Investment Thesis for ALVR?

The company's lead product, posoleucel, has the potential to address a significant unmet need in immunocompromised patients vulnerable to multiple viral infections. Key value drivers include the successful clinical development and regulatory approval of posoleucel, expansion of the pipeline with ALVR106, ALVR109, ALVR107, and ALVR108, and strategic partnerships to enhance manufacturing and commercialization capabilities. A beta of 0.62 suggests lower volatility than the market. Ongoing catalysts include continued clinical trial progress and potential FDA interactions. Potential risks involve clinical trial setbacks, regulatory hurdles, and competition from alternative therapies.

Based on FMP financials and quantitative analysis

ALVR Key Highlights

AlloVir's lead product, posoleucel, targets six common viruses, addressing a significant unmet need in immunocompromised patients.

• The company's pipeline includes ALVR106 for respiratory viruses, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108, expanding its therapeutic reach.
• AlloVir's allogeneic, off-the-shelf VST therapies offer a readily available treatment option, overcoming limitations of patient-specific approaches.
• The company's focus on cell therapy positions it within a rapidly growing segment of the biotechnology industry.
• With a market capitalization of $49.5M, AlloVir presents a potential growth opportunity within the biotechnology sector.

Who Are ALVR's Competitors?

ALVR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALVR's Key Strengths?

Innovative allogeneic VST therapy platform.

• Lead product, posoleucel, targets multiple viruses.
• Strong intellectual property portfolio.
• Experienced management team.

What Are ALVR's Weaknesses?

Clinical-stage company with no approved products.

• Reliance on successful clinical trial outcomes.
• Limited financial resources.
• Small number of employees.

What Could Drive ALVR Stock Higher?

Publication of clinical trial results for posoleucel in peer-reviewed journals.

• Enrollment and data readout from ongoing Phase 3 clinical trials for posoleucel.
• FDA interactions regarding potential regulatory pathways for AlloVir's pipeline candidates.

What Are the Key Risks for ALVR?

Financial-distress signal — its Altman Z-Score of -2.36 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-72.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial setbacks or failures.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies and alternative therapies.
• Intellectual property challenges and patent disputes.
• Dependence on key personnel and the ability to attract and retain talent.

What Are the Growth Opportunities for ALVR?

• Expansion of Posoleucel's Indications: AlloVir has the opportunity to expand the indications for posoleucel beyond its current targets of BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. By demonstrating efficacy against additional viral infections, AlloVir can broaden the market potential for posoleucel and address a wider range of unmet medical needs. This expansion could involve additional clinical trials and regulatory approvals, potentially increasing the commercial value of posoleucel.
• Advancement of Pipeline Candidates: AlloVir's pipeline includes several promising candidates, such as ALVR106 for respiratory syncytial virus (RSV), influenza, parainfluenza virus, and human metapneumovirus; ALVR109 for SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. Successfully advancing these candidates through clinical development and obtaining regulatory approvals would significantly enhance AlloVir's product portfolio and revenue potential. Each candidate targets a substantial market, offering opportunities for growth and diversification.
• Strategic Partnerships and Collaborations: AlloVir can pursue strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other organizations to accelerate the development and commercialization of its VST therapies. These partnerships can provide access to additional funding, expertise, and resources, enabling AlloVir to expand its reach and impact. Collaborations may involve joint research programs, licensing agreements, or co-marketing arrangements.
• Geographic Expansion: AlloVir has the opportunity to expand its geographic presence beyond its current focus in the United States. By entering new markets in Europe, Asia, and other regions, AlloVir can tap into a larger patient population and increase its revenue potential. Geographic expansion may involve establishing local subsidiaries, partnering with distributors, or licensing its products to international companies.
• Technological Innovation: AlloVir can continue to invest in technological innovation to improve the efficacy, safety, and manufacturability of its VST therapies. This may involve developing new cell engineering techniques, optimizing manufacturing processes, or exploring novel delivery methods. Technological advancements can enhance AlloVir's competitive advantage and create new opportunities for growth.

What Are ALVR's Competitive Advantages?

• Proprietary VST therapy platform.
• Patent protection for posoleucel and other pipeline candidates.
• Expertise in cell therapy manufacturing and development.
• First-mover advantage in targeting multiple viruses with a single therapy.

What Does ALVR Do?

AlloVir, Inc., formerly known as ViraCyte, Inc., was founded in 2013 and is headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing allogeneic, off-the-shelf, multi-virus specific T cell (VST) therapies to combat viral-associated diseases. AlloVir's primary focus is on addressing the unmet needs of immunocompromised patients who are at high risk for life-threatening viral infections. Their lead product candidate, posoleucel, is designed to target six common viruses: BK virus, cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and JC virus. Posoleucel aims to provide a readily available, off-the-shelf therapeutic option to manage and prevent these viral infections in patients post-transplant or with weakened immune systems. In addition to posoleucel, AlloVir is advancing a pipeline of VST therapies, including ALVR106 targeting respiratory syncytial virus (RSV), influenza, parainfluenza virus, and human metapneumovirus; ALVR109 for SARS-CoV-2 and COVID-19; ALVR107 for hepatitis B; and ALVR108. AlloVir's approach leverages its expertise in cell therapy to offer innovative solutions for preventing and treating severe viral diseases, positioning it as a key player in the biotechnology landscape.

What Products and Services Does ALVR Offer?

• Develops allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies.
• Focuses on preventing and treating viral-associated diseases.
• Lead product, posoleucel, targets BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
• Pipeline includes ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus.
• Developing ALVR109 to treat SARS-CoV-2 and COVID-19.
• Researching ALVR107 for treating hepatitis B.
• Exploring ALVR108 for additional viral targets.

How Does ALVR Make Money?

• Develops and patents allogeneic cell therapies.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA.
• Commercializes approved therapies through sales and marketing.

What Industry Does ALVR Operate In?

AlloVir operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for cell therapies is expanding, driven by advancements in immunotherapy and regenerative medicine. AlloVir's focus on allogeneic, off-the-shelf VST therapies positions it to compete with companies developing patient-specific cell therapies and antiviral drugs. The biotechnology industry is subject to stringent regulatory requirements and faces challenges related to clinical trial success and commercialization. AlloVir's success depends on its ability to navigate these challenges and establish a strong market presence.

Who Are ALVR's Key Customers?

• Immunocompromised patients at risk of viral infections.
• Patients undergoing transplants.
• Hospitals and medical centers.
• Healthcare providers specializing in infectious diseases.

AlloVir, Inc. Financial Trajectory

AlloVir, Inc. (ALVR) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $11.5M, with diluted EPS of $-0.48. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ALVR averaged $-0.43 in diluted EPS.

Company Profile

AlloVir, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Vikas Sinha CPA,. ALVR has traded publicly since 2020.

How AlloVir, Inc. Is Valued

AlloVir, Inc. carries a market capitalization of $49.5M, placing it in the micro-cap category.

Return on equity for AlloVir, Inc. stands at -72.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -53.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -37.6%, the inverse of the P/E and a quick read on earnings relative to price.

AlloVir, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.36 places it in the distress zone, a signal of elevated financial risk.

AlloVir, Inc. has beaten Wall Street's EPS estimate in 4 of its last 5 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 668.6% below estimates on average.

The most recent 12 insider filings for AlloVir, Inc. break down as 12 sales and 0 purchases. On net that is roughly 2K shares disposed (about $8K), a signal worth weighing alongside the fundamentals.

ALVR Financials

ALVR Latest News

AlloVir, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources